Generer rapport
Takeda Pharma A/S
Delta Park 45, 2665 Vallensbæk Strand, CVR 16406899
Virksomhedsform
Aktieselskab
Etableret
1984
Størrelse
Mellemstore
Ansatte
70
Omsætning
1.061
MDKK
Bruttofortj.
121
MDKK
Primært resultat (EBIT)
21
MDKK
Årets resultat
14
MDKK
Egenkapital
95
MDKK
annonce
Flere nøgletal og analyser?
Med en Bisbase Premium konto får du flere nøgletal for både virksomheder, koncerner og brancher samt adgang til eksklusive brancher indeholdende virksomheder nøje sammensat af eksperter. Og vil du lave dine egne analyser kan du også det! Det tager få minutter at få adgang - og det behøver ikke at koste dig noget!
Rang Årets resultat
Rang i branche
49/444
"Top 35%"
Rang i Danmark
9.357/342.443
"Top 10%"
Direktion top 3
Roland Kurney 1 | CEO |
Bestyrelse top 3
Vatroslav Mateljic 1 | Bestyrelsesformand |
Jesper Lindahl 1 | Bestyrelsesmedlem |
Christian Ramskov 1 | Bestyrelsesmedlem |
Legale ejere top 3
Tegningsregler
Selskabet tegnes af en direktør, af tre medlemmer af bestyrelsen i forening, af bestyrelsens formand og et andet medlem af bestyrelsen i forening eller af den samlede bestyrelse.
Stamoplysninger baseret på CVR
Navn | Takeda Pharma A/S |
Binavne | Ab Pharma A/S, Basoderm A/S, Benzon Bio-Tech A/S, Benzon Biosystems A/S, Benzon Pharma A/S, Dak Laboratories A/S, Danimed A/S, Nettopharma A/S, Nycomed Benzon A/S, Nycomed Consumer A/S, Nycomed Dak A/S, Nycomed Danmark A/S, Nycomed Dk A/S, Nycomed Pharma A/S, Nycomed Pharma-Medica A/S, Pharma-Medica A/S, Pharmachemie A/S, Shire Denmark A/S, Takeda Pharmaceuticals Denmark A/S, Ab Pharma Aps, Basoderm Aps, Benzon Bio-Tech Aps, Benzon Biosystems Aps, Benzon Pharma Aps, Dak Laboratories Aps, Dak-Laboratoriet A/S, Danimed Aps, Nycomed A/S, Nycomed Aps, Nycomed Benzon Aps, Nycomed Dak Aps, Nycomed Dk Aps, Nycomed Pharma Aps, Nycomed Pharma-Medica Aps, Pharma-Medica Aps, Takeda Pharmaceuticals Denmark Aps Vis mere |
CVR | 16406899 |
Adresse | Delta Park 45, 2665 Vallensbæk Strand |
Branche | Engroshandel med medicinalvarer og sygeplejeartikler [464610] |
Etableret | 02-01-1984 (40 år) |
Første regnskabsperiode | 02-01-1984 til 31-12-1984 |
Virksomhedsform | Aktieselskab |
Antal ansatte | 72 (årsværk:65) |
Reklamebeskyttelse | Nej |
Revisor | Kpmg P/S siden 20-11-2014 |
Regnskabsperiode | 01-04 til 31-03 |
Selskabskapital | 10.100.000 DKK 10.000.000 DKK (30-03-2019 - 31-03-2020) 956.100.000 DKK (16-03-2016 - 29-03-2019) 810.100.000 DKK (23-12-2014 - 15-03-2016) 810.000.000 DKK (08-11-2012 - 22-12-2014) 809.000.000 DKK (19-06-2012 - 07-11-2012) |
Vedtægter seneste | 25-04-2023 |
Medlem af brancherne
- Engroshandel med medicinalvarer og sygeplejeartiklerNACE6 indeholdende 632 virk.
- Engroshandel med husholdningsartiklerNACE3 indeholdende 6.348 virk.
- Engroshandel undtagen med motorkøretøjer og motorcyklerNACE2 indeholdende 24.387 virk.
- Engroshandel og detailhandel, reparation af motorkøretøjer og motorcyklerNACE1 indeholdende 75.353 virk.
Formål
Selskabets formål er udvikling og fremstilling af samt handel med lægemidler og hermed beslægtede varer.
Regnskab
2023 | 2022 | 2021 | |
---|---|---|---|
Valuta/enhed | 000' DKK | 000' DKK | 000' DKK |
Omsætning | 1.061.206 +17% | 910.058 -53% | 1.939.231 +24% |
Bruttofortjeneste | 120.582 -22% | 153.989 -86% | 1.134.904 -64% |
Årets resultat | 13.573 -57% | 31.795 -95% | 667.744 -75% |
Egenkapital | 94.892 +17% | 81.238 -92% | 1.046.401 -61% |
Balance | 485.750 -22% | 622.293 -69% | 2.017.020 -47% |
Ledelsesberetning
Management’s Review
Development in the yearThe income statement of the Company for 2022/23 shows a profit of DKK 24,222k, and at 31 March 2023 the balance sheet of the Company shows equity of DKK 105,541k.The past year and follow-up on development expectations from last yearOperating profit for the year is in line with the expectations and there has not been any major single events influencing the result.Operating risks and financial risksOperating risksManagement teams in Takeda Pharma A/S as well as the Group are responsible for monitoring and assessing potential business risks that may arise.The Company's activities are subject to rigorous regulatory control and approval procedures. Moreover, the ongoing cost management by public authorities and the health sector will result in lower prices and reimbursements in the future. Management continuously monitors the development and assesses the effect.Future growth and success will depend on Takeda's ability to develop new products and the local companies' ability to market these products. Moreover, the development of sales in the existing product portfolio will be essential to the financial performance of Takeda Pharma A/S.Credit risksThe financial risks of Takeda Pharma A/S are administered in accordance with the policies and instructions adopted by the Group. Accordingly, credit risks and outstanding payments are evaluated continuously.Financial risks are administered centrally in the Group. The Group does not carry out financial transactions that are not related to hedging of the underlying business risks. It is thus not the Group's policy to engage in active speculation in financial risks.Targets and expectations for the year aheadThe company expects the underlying profit in the financial year 2023/24 on the same level as the financial year 2022/23.
Development in the yearThe income statement of the Company for 2022/23 shows a profit of DKK 24,222k, and at 31 March 2023 the balance sheet of the Company shows equity of DKK 105,541k.The past year and follow-up on development expectations from last yearOperating profit for the year is in line with the expectations and there has not been any major single events influencing the result.Operating risks and financial risksOperating risksManagement teams in Takeda Pharma A/S as well as the Group are responsible for monitoring and assessing potential business risks that may arise.The Company's activities are subject to rigorous regulatory control and approval procedures. Moreover, the ongoing cost management by public authorities and the health sector will result in lower prices and reimbursements in the future. Management continuously monitors the development and assesses the effect.Future growth and success will depend on Takeda's ability to develop new products and the local companies' ability to market these products. Moreover, the development of sales in the existing product portfolio will be essential to the financial performance of Takeda Pharma A/S.Credit risksThe financial risks of Takeda Pharma A/S are administered in accordance with the policies and instructions adopted by the Group. Accordingly, credit risks and outstanding payments are evaluated continuously.Financial risks are administered centrally in the Group. The Group does not carry out financial transactions that are not related to hedging of the underlying business risks. It is thus not the Group's policy to engage in active speculation in financial risks.Targets and expectations for the year aheadThe company expects the underlying profit in the financial year 2023/24 on the same level as the financial year 2022/23.
19-09-2023